Gene mutational pattern and expression level in 560 acute myeloid leukemia patients and their clinical relevance

CBF -SMMHC creates aberrant megakaryocyte-erythroid progenitors prone to leukemia initiation in mice

(2016) Q. Cai et al.   BLOOD

Spectrum and prognostic relevance of driver gene mutations in acute myeloid leukemia

(2016) K. H. Metzeler et al.   BLOOD

Genomic Classification and Prognosis in Acute Myeloid Leukemia

(2016) Elli Papaemmanuil et al.   NEW ENGLAND JOURNAL OF MEDICINE

Kinase-associated gene mutation pattern and clinical relevance in 205 patients with core binding factor leukemias

(2016) Y-S Chen et al.   Blood Cancer Journal

MEIS1 regulates an HLF-oxidative stress axis in MLL-fusion gene leukemia

(2015) J. Roychoudhury et al.   BLOOD

High expression of EVI1 and MEL1 is a compelling poor prognostic marker of pediatric AML

(2015) A Jo et al.   LEUKEMIA

Mutations of Epigenetic Modifier Genes as a Poor Prognostic Factor in Acute Promyelocytic Leukemia Under Treatment With All-Trans Retinoic Acid and Arsenic Trioxide

(2015) Yang Shen et al.   EBioMedicine

A Remote GATA2 Hematopoietic Enhancer Drives Leukemogenesis in inv(3)(q21;q26) by Activating EVI1 Expression

(2014) Hiromi Yamazaki et al.   CANCER CELL

EVI1 overexpression is a poor prognostic factor in pediatric patients with mixed lineage leukemia-AF9 rearranged acute myeloid leukemia

(2014) H. Matsuo et al.   HAEMATOLOGICA

Minimal residual disease monitored after induction therapy by RQ-PCR can contribute to tailor treatment of patients with t(8;21) RUNX1-RUNX1T1 rearrangement

(2014) M. Pigazzi et al.   HAEMATOLOGICA

Metallothionein III (MT3) is a putative tumor suppressor gene that is frequently inactivated in pediatric acute myeloid leukemia by promoter hypermethylation

(2014) Yan-Fang Tao et al.   Journal of Translational Medicine

WT1 mutations are secondary events in AML, show varying frequencies and impact on prognosis between genetic subgroups

(2014) M-T Krauth et al.   LEUKEMIA

Bone marrow WT1 levels at diagnosis, post-induction and post-intensification in adult de novo AML

(2013) J F Nomdedéu et al.   LEUKEMIA

The role of different genetic subtypes of CEBPA mutated AML

(2013) A Fasan et al.   LEUKEMIA

Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid Leukemia

(2013)   NEW ENGLAND JOURNAL OF MEDICINE

Minimal residual disease monitoring by quantitative RT-PCR in core binding factor AML allows risk stratification and predicts relapse: results of the United Kingdom MRC AML-15 trial

(2012) J. A. L. Yin et al.   BLOOD

New Strategies in Acute Myeloid Leukemia: Redefining Prognostic Markers to Guide Therapy

(2012) I. Khan et al.   CLINICAL CANCER RESEARCH

Prognostic Significance of the European LeukemiaNet Standardized System for Reporting Cytogenetic and Molecular Alterations in Adults With Acute Myeloid Leukemia

(2012) Krzysztof Mrózek et al.   JOURNAL OF CLINICAL ONCOLOGY

Mutations of the epigenetics-modifying gene (DNMT3a, TET2, IDH1/2) at diagnosis may induce FLT3-ITD at relapse in de novo acute myeloid leukemia

(2012) S Wakita et al.   LEUKEMIA

The clinical relevance of BAALC and ERG expression levels in pediatric AML

(2012) M C H Hermkens et al.   LEUKEMIA

Prognostic Relevance of Integrated Genetic Profiling in Acute Myeloid Leukemia

(2012) Jay P. Patel et al.   NEW ENGLAND JOURNAL OF MEDICINE

Gene mutation patterns and their prognostic impact in a cohort of 1185 patients with acute myeloid leukemia

(2011) Y. Shen et al.   BLOOD

Integrative prognostic risk score in acute myeloid leukemia with normal karyotype

(2011) F. Damm et al.   BLOOD

An accumulation of cytogenetic and molecular genetic events characterizes the progression from MDS to secondary AML: an analysis of 38 paired samples analyzed by cytogenetics, molecular mutation analysis and SNP microarray profiling

(2011) J Flach et al.   LEUKEMIA

BAALC and ERG expression levels are associated with outcome and distinct gene and microRNA expression profiles in older patients with de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study

(2010) S. Schwind et al.   BLOOD

Acute Myeloid Leukemia With Translocation (8;21) or Inversion (16) in Elderly Patients Treated With Conventional Chemotherapy: A Collaborative Study of the French CBF-AML Intergroup

(2009) Thomas Prébet et al.   JOURNAL OF CLINICAL ONCOLOGY

Real-Time Quantitative Polymerase Chain Reaction Detection of Minimal Residual Disease by StandardizedWT1Assay to Enhance Risk Stratification in Acute Myeloid Leukemia: A European LeukemiaNet Study

(2009) Daniela Cilloni et al.   JOURNAL OF CLINICAL ONCOLOGY

When can real-time quantitative RT-PCR effectively define molecular relapse in acute promyelocytic leukemia patients? (Results of the French Belgian Swiss APL Group)

(2009) Bruno Cassinat et al.   LEUKEMIA RESEARCH

A role for MEIS1 in MLL-fusion gene leukemia

(2008) A. R. Kumar et al.   BLOOD

Emerging treatment strategies for acute myeloid leukemia (AML) in the elderly

(2008) Andrea Kuendgen et al.   CANCER TREATMENT REVIEWS

Favorable prognostic impact of NPM1 gene mutations in childhood acute myeloid leukemia, with emphasis on cytogenetically normal AML

(2008) I H I M Hollink et al.   LEUKEMIA

Mutations and Treatment Outcome in Cytogenetically Normal Acute Myeloid Leukemia

(2008) Richard F. Schlenk et al.   NEW ENGLAND JOURNAL OF MEDICINE